Alterity Therapeutics (ATHE) Cash & Equivalents (2009 - 2025)

Alterity Therapeutics' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $32.3 million for Q4 2025.

• On a quarterly basis, Cash & Equivalents rose 988.88% year-over-year to $32.3 million in Q4 2025; TTM through Dec 2025 was $32.3 million, a 988.88% increase from a year earlier, with the FY2025 full-year figure at $21.2 million, up 154.95% from the prior year.
• Cash & Equivalents grew to $32.3 million in Q4 2025 per ATHE's latest filing, from $21.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $32.3 million in Q4 2025 and bottomed at $126388.8 in Q2 2024.
• The 5-year median for Cash & Equivalents is $21.4 million (2021), against an average of $16.3 million.
• Across the five-year window, Cash & Equivalents plunged 99.37% in 2023 and jumped 16702.03% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $27.0 million in 2021, then dropped by 15.16% to $22.9 million in 2022, then tumbled by 55.1% to $10.3 million in 2023, then plunged by 71.11% to $3.0 million in 2024, then jumped by 988.88% to $32.3 million in 2025.
• Per Business Quant, the three latest ATHE Cash & Equivalents figures stand at $32.3 million (Q4 2025), $21.2 million (Q2 2025), and $3.0 million (Q4 2024).